Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

254
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
254
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

69
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
69
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

123
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
123
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

62
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
62
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

70
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
70
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

672
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
672

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Comprehensive analysis of IGFL1 in colorectal cancer and its promotion of tumour progression via inhibition of lipophagy.

Frontiers in immunology·2026
Same author

Integrative chromosome-level genomics and metabolomics uncover regulatory networks linking monoterpenoid biosynthesis and glandular trichome formation in <i>Mosla chinensis</i>.

Horticulture research·2026
Same author

Global burden and cross-country inequalities of age-related eye diseases from 1990 to 2021: a comprehensive analysis of temporal trends and socioeconomic disparities.

Eye and vision (London, England)·2026
Same author

Confinement and Encapsulation of Nano-Sn in a Multimodal Porous Carbon Matrix for High-Performance Sodium-Ion Batteries.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Associations of relative fat mass with metabolic dysfunction-associated steatotic liver disease and liver fibrosis: evidence from the U.S. NHANES 2017-2023.

BMC gastroenterology·2026
Same author

Dynamic ctDNA Monitoring Guides Early Treatment Intensification in Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemotherapy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

相关实验视频

Updated: Jun 30, 2025

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

6.6K

CPhaMAS:基于优化的参数拟合算法进行药理学数据分析的在线平台.

Yun Kuang1, Dong-Sheng Cao2, Yong-Hui Zuo3

  • 1Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, 410013, China; XiangYa School of Pharmaceutical Sciences, Central South University, Changsha, 410083, China.

Computer methods and programs in biomedicine
|March 23, 2024
PubMed
概括
此摘要是机器生成的。

CPhaMAS提供了一个易于使用的药理动力学分析平台,具有优化的Nelder-Mead算法,用于药物开发中准确的参数估计. 该工具简化了研究人员和临床医生的复杂数据分析.

关键词:
在CPhaMAS中使用.在线平台在线平台.优化纳尔德-米德方法药物动力学数据分析

更多相关视频

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology
06:24

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology

Published on: December 15, 2017

10.0K
PTR-ToF-MS Coupled with an Automated Sampling System and Tailored Data Analysis for Food Studies: Bioprocess Monitoring, Screening and Nose-space Analysis
08:43

PTR-ToF-MS Coupled with an Automated Sampling System and Tailored Data Analysis for Food Studies: Bioprocess Monitoring, Screening and Nose-space Analysis

Published on: May 11, 2017

12.4K

相关实验视频

Last Updated: Jun 30, 2025

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

6.6K
Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology
06:24

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology

Published on: December 15, 2017

10.0K
PTR-ToF-MS Coupled with an Automated Sampling System and Tailored Data Analysis for Food Studies: Bioprocess Monitoring, Screening and Nose-space Analysis
08:43

PTR-ToF-MS Coupled with an Automated Sampling System and Tailored Data Analysis for Food Studies: Bioprocess Monitoring, Screening and Nose-space Analysis

Published on: May 11, 2017

12.4K

科学领域:

  • 药理学和药物开发领域
  • 计算生物学和生物信息学
  • 生物统计学 生物统计学

背景情况:

  • 临床药理学建模软件至关重要,但通常具有的学习曲线.
  • 现有的算法与个体差异和测量错误作斗争,阻碍了准确的药理动力学参数估计.
  • 对于药物开发和个性化治疗,需要具有强大的参数匹配的用户友好型工具.

研究的目的:

  • 开发一个优化的参数拟合算法,对初始值不那么敏感.
  • 将这个算法集成到一个名为CPhaMAS的用户友好的在线平台中,用于药理动力学数据分析.
  • 与现有软件相比,评估CPhaMAS平台的性能和准确性.

主要方法:

  • 开发了一个优化的Nelder-Mead方法,其中包括简单顶点的重新初始化,以避免局部解决方案.
  • 优化的算法被集成到CPhaMAS平台中,该平台包括用于隔间模型分析,非隔间分析 (NCA) 和生物等价性/生物可用性 (BE/BA) 分析的模块.
  • 评估了CPhaMAS平台,并与已建立的WinNonlin软件进行了比较.

主要成果:

  • CPhaMAS展示了易于使用,不需要编程知识.
  • 优化的Nelder-Mead方法在CPhaMAS中显示出优异的准确性 (较低的平均相对误差,较高的R2),与WinNonlin相比,在两和外血管模型中,即使具有异常的初始值.
  • 与WinNonlin相比,CPhaMAS中NCA参数计算的平均相对误差为<0.0001%,不同类型药物的BE计算显示关键参数 (Cmax,AUCt,AUCinf) 的平均相对误差为<0.01% .

结论:

  • CPhaMAS 是一个用户友好且准确的药理动力学数据分析平台.
  • 集成的优化算法提高了参数估计的可靠性.
  • CPhaMAS是药物开发和精密医学的宝贵工具.